Achieve Life Sciences Q3 2026 Results: Net Loss of $12.1M, Loss Narrows
Achieve Life Sciences significantly strengthened its liquidity position, ending September 30, 2026, with $201.5 million in cash and marketable securities compared to $36.4 million at the end of 2025. The company is focused on its NDA resubmission for cytisinicline following a CRL and is currently involved in arbitration with its supplier, Sopharma.
- Key figure
- Net loss $12.1M